NEUROSARCOMA FOLLOWING VONRECKLINGHAUSEN DISEASE - THE INSTITUTE-GUSTAVE-ROUSSY EXPERIENCE 1967-1990

被引:0
|
作者
VITACCA, SA
SARRAZIN, D
HENRYAMAR, M
SPIELMANN, M
GENIN, J
BERNHEIM, A
CONTESSO, G
机构
[1] INST GUSTAVE ROUSSY, DEPT RADIOTHERAPIE, 39-53 RUE CAMILLE DESMOULINS, F-94805 VILLEJUIF, FRANCE
[2] INST GUSTAVE ROUSSY, DEPT BIOSTAT & EPIDEMIOL, F-94805 VILLEJUIF, FRANCE
[3] INST GUSTAVE ROUSSY, DEPT MED, F-94805 VILLEJUIF, FRANCE
[4] INST GUSTAVE ROUSSY, DEPT CHIRURG GEN, F-94805 VILLEJUIF, FRANCE
[5] INST GUSTAVE ROUSSY, DEPT ANAT PATHOL, F-94805 VILLEJUIF, FRANCE
[6] INST GUSTAVE ROUSSY, CYTOGENET LAB, F-94805 VILLEJUIF, FRANCE
关键词
NEUROSARCOMA; VONRECKLINGHAUSEN DISEASE; CLINICAL OUTCOME;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the absence of systematic immunohistochemistry investigations, only 25 cases (out of 69) clearly diagnosed as neurosarcoma due to the association with Von Recklinghausen disease (ie, neurofibromatosis type 1) and treated at the Institut Gustave Roussy were included in the present study. Neurosarcoma consists of a neurocristopathy whose cells migrate to several parts of the body in order to constitute neuroglia, Schwann cells, pigmented and endocrinal tissues. From 1967 to 1990, 25 cases of such neurosarcomas associated with a neurofibromatosis type 1 were seen at our institute. Three different histological terms exist for this tumour: malignant schwannoma, neurosarcoma, and more recently, malignant peripheral nerve sheath tumours (MPNST). The median age (23 years) of the patients with neurofibromatosis type 1 is lower than that of patient with isolated neurosarcoma. Their sex ratio is 2/1. Primary tumour surgical exeresis was performed in all cases, with poor results in 7. Post-operative radiation therapy was not systematically used in this series. It was administered only in cases with incomplete surgical exeresis or when a local recurrence occurred. Adjuvant CYVADIC (doxorubicin, procarbazine, cyclophosphamide, vincristine) chemotherapy was administered in 5 cases, of in cases of relapse (8). All cases but 2 (the most recent ones) relapsed within 1 to 226 months (median 7 months). In addition, 13 patients developed metastases. Overall, the 2-year and 4-year survival rates were 41% and 18%, respectively. Our observations confirm the very poor prognosis for the association of neurofibromatosis type 1 and neurosarcoma. This finding should lead to systematically associate radical surgical exeresis, post-operative irradiation and adjuvant chemotherapy in the treatment of these patients.
引用
收藏
页码:101 / 112
页数:12
相关论文
共 38 条
  • [21] Inhaled iterative anesthesia for radiotherapy in children: review of 16 years of experience in the Gustave-Roussy institute
    Gomas, F.
    Billard, V.
    Baguenard, P.
    Grill, J.
    Boll, S.
    Muret, J.
    Bourgain, J. -L.
    ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION, 2013, 32 : A31 - A32
  • [22] HIGH-DOSE COMBINATION ALKYLATING AGENTS IN PAEDIATRIC RHABDOMYOSARCOMA: THE GUSTAVE ROUSSY INSTITUTE EXPERIENCE.
    Dourthe, M. E.
    Oberlin, O.
    Dufour, C.
    Rey, A.
    Canale, S.
    Martelli, H.
    Valteau-couanet, D.
    Minard-colin, V.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : 93 - 93
  • [23] COLLOQUIUM ON TECHNICAL DEVELOPMENT OF CURIE-THERAPY IN GYNECOLOGY - USE OF CESIUM 137 IN GYNECOLOGY (INSTITUTE GUSTAVE ROUSSY 21 OCTOBER 1967)
    PIERQUIN, B
    ANNALES DE RADIOLOGIE-RADIOLOGIE CLINIQUE RADIOBIOLOGIE, 1967, 10 (11-1): : R865 - &
  • [24] 105 cases of renal tumors in patients age 15 to 35: A specific entity? Experience of the Gustave Roussy Institute
    Dariane, Charles
    Pasqualini, Claudia
    Gaspar, Nathalie
    Brugieres, Laurence
    Patte, Catherine
    Patard, Jean Jacques
    Baumert, Herve
    Loriot, Yohann
    Massard, Christophe
    Fizazi, Karim
    Merabet, Zahira
    Di Palma, Mario
    Escudier, Bernard J.
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] RENDU-OSLER DISEASE - DESCRIPTION OF 50 CASES FOLLOWED UP AT GUSTAVE-ROUSSY-INSTITUTE
    CACHIN, Y
    SAUVAGE, JP
    SCHWAAB, G
    ANNALES D OTO-LARYNGOLOGIE ET DE CHIRURGIE CERVICO-FACIALE, 1976, 93 (1-2): : 103 - 108
  • [26] ANTIVIRAL APPROACHES TO TREAT HPV RELATED TUMORS : THE INSTITUTE GUSTAVE ROUSSY EXPERIENCE FROM PRECLINICAL DATA TO CLINICAL TRIALS
    Deutsch, E.
    Vozenin-Brotons, M. C.
    Morice, P.
    Lhomme, C.
    Pautier, P.
    Deberne, M.
    Soria, J. C.
    Haie-Meder, C.
    Bourhis, J.
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S231 - S231
  • [27] The SARS-CoV-2 vaccine and enrollment of patients with cancer in phase I trials: The experience at Institute Gustave Roussy
    Belcaid, L.
    Baldini, C.
    Laparra, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S18 - S18
  • [28] Brachytherapy for T1-T2 floor-of-the-mouth cancers: The Gustave-Roussy Institute experience
    Marsiglia, H
    Haie-Meder, C
    Sasso, G
    Mamelle, G
    Gerbaulet, A
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (05): : 1257 - 1263
  • [29] A STUDY OF RELAPSE AND COURSE OF 153 CASES OF HODGKINS-DISEASE (CLINICAL STAGES-1 AND STAGE-2) TREATED AT THE INSTITUTE-GUSTAVE-ROUSSY FROM 1963 TO 1970 WITH RADIOTHERAPY ALONE OR WITH ADJUVANT MONOCHEMOTHERAPY
    PENE, F
    HENRYAMAR, M
    LEBOURGEOIS, JP
    HAYAT, M
    GERARDMARCHANT, R
    LAUGIER, A
    MATHE, G
    TUBIANA, M
    CANCER, 1980, 46 (10) : 2131 - 2141
  • [30] ANTIVIRAL APPROACHES TO TREAT HPV RELATED TUMORS: THE INSTITUTE GUSTAVE ROUSSY EXPERIENCE FROM PRECLINICAL DATA TO CLINICAL TRIALS
    Deutsch, E.
    Vozenin, M. C.
    RADIOTHERAPY AND ONCOLOGY, 2012, 102 : S187 - S187